- Home
- LVLU vs SNY Comparison
LVLU vs SNY Comparison
Compare LVLU & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- SNY
- Stock Information
- Founded
- LVLU 1996
- SNY 1994
- Country
- LVLU United States
- SNY France
- Employees
- LVLU N/A
- SNY N/A
- Industry
- LVLU Catalog/Specialty Distribution
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- SNY Health Care
- Exchange
- LVLU Nasdaq
- SNY Nasdaq
- Market Cap
- LVLU 18.4M
- SNY 116.5B
- IPO Year
- LVLU 2021
- SNY N/A
- Fundamental
- Price
- LVLU $4.33
- SNY $48.70
- Analyst Decision
- LVLU Hold
- SNY Buy
- Analyst Count
- LVLU 2
- SNY 2
- Target Price
- LVLU $1.00
- SNY $62.50
- AVG Volume (30 Days)
- LVLU 58.3K
- SNY 2.1M
- Earning Date
- LVLU 08-13-2025
- SNY 07-24-2025
- Dividend Yield
- LVLU N/A
- SNY 3.32%
- EPS Growth
- LVLU N/A
- SNY 39.56
- EPS
- LVLU N/A
- SNY 5.45
- Revenue
- LVLU $302,783,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- LVLU N/A
- SNY $3.39
- Revenue Next Year
- LVLU $2.53
- SNY $7.05
- P/E Ratio
- LVLU N/A
- SNY $8.84
- Revenue Growth
- LVLU N/A
- SNY N/A
- 52 Week Low
- LVLU $3.30
- SNY $45.80
- 52 Week High
- LVLU $28.20
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- LVLU 39.28
- SNY 46.62
- Support Level
- LVLU $3.30
- SNY $47.99
- Resistance Level
- LVLU $5.43
- SNY $49.37
- Average True Range (ATR)
- LVLU 1.33
- SNY 0.60
- MACD
- LVLU -0.11
- SNY 0.14
- Stochastic Oscillator
- LVLU 20.20
- SNY 65.64
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.